Related Experiment Video
Updated: May 30, 2026

Isolation of Mesenchymal Stem Cells from Human Alveolar Periosteum and Effects of Vitamin D on Osteogenic Activity of Periosteum-derived Cells
Published on: May 4, 2018
High-dose cholecalciferol supplementation for vitamin D deficiency in haemodialysis patients
E Jakopin1, B Pecovnik Balon, R Ekart
1Department of Nephrology, University Medical Centre Maribor, Maribor, Slovenia. e.jakopin@gmail.com
Insights
High-dose monthly vitamin D(3) supplementation in haemodialysis patients was safe and well-tolerated. However, this regimen was insufficient to correct mild or severe vitamin D deficiency in these individuals.
Area of Science:
- Nephrology
- Endocrinology
- Nutritional Science
Background:
- Vitamin D deficiency is prevalent in haemodialysis (HD) patients, linked to increased mortality.
- Current guidelines for vitamin D supplementation in HD patients are lacking.
Purpose of the Study:
- To evaluate the efficacy of monthly high-dose cholecalciferol (vitamin D(3)) supplementation in HD patients.
- To assess the safety and tolerability of this supplementation regimen.
Main Methods:
- Patients with 25-hydroxy vitamin D (25[OH]D) < 75 nmol/l received 40,000 IU of cholecalciferol monthly for 3 months.
- Treatment was continued in cycles based on 4-monthly 25(OH)D level assessments over 24 months.
Main Results:
- The majority of HD patients presented with mild or severe vitamin D deficiency at baseline.
- Monthly 40,000 IU cholecalciferol was safe, well-tolerated, and inexpensive.
- The regimen effectively addressed vitamin D insufficiency but did not fully restore 25(OH)D levels in patients with mild or severe deficiency.
Conclusions:
- Monthly high-dose cholecalciferol is a safe and cost-effective option for vitamin D insufficiency in HD patients.
- This dosage and frequency may not be sufficient to correct established mild or severe vitamin D deficiency in this population.
Abstract:
Vitamin D deficiency, which is a recognized problem in haemodialysis (HD) patients, has been associated with higher all-cause mortality. There are no guidelines concerning vitamin D supplementation in HD patients. This study aimed to assess the effects of once-monthly supplementation with high-dose cholecalciferol (vitamin D(3)) in HD patients. Patients with 25-hydroxy vitamin D (25[OH]D) levels of < 75 nmol/l received 40,000 IU of cholecalciferol oncemonthly for 3 months in succession. Every 4 months, 25(OH)D levels were measured and, based on the findings, cholecalciferol therapy was continued for another cycle if necessary. Six cycles were completed in the 24-month study period. The majority of HD patients had mild or severe vitamin D deficiency at baseline. Monthly supplementation with cholecalciferol at 40,000 IU was well tolerated, safe and inexpensive. The treatment regime was effective for vitamin D insufficiency but did not prove to be enough to restore 25(OH)D levels in HD patients with mild or severe vitamin D deficiency.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Hemodialysis III: Nursing Management
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Hemodialysis II: Procedure and Complications
Chronic Kidney Disease IV: Nursing Management
